Paul Dorman - RXi Pharmaceuticals Independent Director
Director
Mr. H. Paul Dorman is an Independent Director of RXI Pharmaceuticals Corporationrationration. Mr. Dorman has served as a member of our Board of Directors since April 2013. Mr. Dorman currently serves as the Chairman and CEO of DFB Pharmaceuticals, a holdings company specializing in investing in and operating pharmaceutical businesses. From 1990 to 2012, Mr. Dorman also served as the Chairman and CEO of DPT Laboratories, a contract manufacturer and developer of pharmaceutical products. During that time, Mr. Dorman expanded DPT into a portfolio of healthcare companies that provides services and proprietary branded pharmaceutical products to the global market. Prior to acquiring DPT, Mr. Dorman was employed by Johnson Johnson for 12 years, where he served in various positions, including Vice President and as a member of the board of directors. Prior to Johnson Johnson, Mr. Dorman was employed by BaxterTravenol, a large pharmaceuticals company since 2013.
| Age | 78 |
| Tenure | 11 years |
| Phone | 508-767-3861 |
| Web | http://www.rxipharma.com |
RXi Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Timothy Guertin | Teradyne | 68 | |
| Barry Allen | BCE Inc | 70 | |
| Kenton Sicchitano | Analog Devices | 73 | |
| Jose Almeida | Analog Devices | 52 | |
| Michael Bradley | Teradyne | 69 | |
| James Gentilcore | Entegris | 65 | |
| Edwin Gillis | Teradyne | 69 | |
| Edward Frank | Analog Devices | 61 | |
| Azita SalekiGerhardt | Entegris | 54 | |
| Robert Simmonds | BCE Inc | 67 | |
| John Hodgson | Analog Devices | 71 | |
| Carole Taylor | BCE Inc | 68 | |
| Daniel Christman | Teradyne | 72 | |
| James Champy | Analog Devices | 75 | |
| Sophie Brochu | BCE Inc | 55 | |
| Sheila Murray | BCE Inc | 65 | |
| Brian Sullivan | Entegris | 56 | |
| Peter Convertito | ASML Holding NV | N/A | |
| Neil Novich | Analog Devices | 63 | |
| Yves Istel | Analog Devices | 79 | |
| Roy Vallee | Teradyne | 65 | |
Management Performance
| Return On Equity | -294.79 | |||
| Return On Asset | -96.79 |
RXi Pharmaceuticals Leadership Team
Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Geert Cauwenbergh, President CEO, Director | ||
| Robert Bitterman, Director | ||
| Pamela Pavco, Chief Devel. Officer | ||
| Keith Brownlie, Director | ||
| Jonathan Freeman, Independent Director | ||
| Gerrit Dispersyn, Chief Development Officer | ||
| Curtis Lockshin, Director | ||
| Paul Dorman, Independent Director | ||
| Alexey Eliseev, Chief Business Officer | ||
| Tamara McGrillen, IR Contact Officer |
RXi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -294.79 | |||
| Return On Asset | -96.79 | |||
| Current Valuation | (1.77 M) | |||
| Shares Outstanding | 18.16 M | |||
| Shares Owned By Insiders | 3.78 % | |||
| Shares Owned By Institutions | 10.08 % | |||
| Number Of Shares Shorted | 814.04 K | |||
| Price To Earning | (0.54) X | |||
| Price To Book | 0.84 X | |||
| Price To Sales | 39.20 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in RXi Stock
If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world |